Synergistic activity of the histone deacetylase inhibitor trichostatin A and the proteasome inhibitor PS-341 against taxane-resistant ovarian cancer cell lines

Although a combination of platinum- and taxane-based chemotherapy is recommended for at least 70% patients with ovarian cancer as treatment subsequent to surgery, the initial response to the chemotherapy is not durable and tumors become resistant. Histone deacetylase and proteasome inhibitors are no...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Xin, Fang, Yong, Hu, Yi, Chen, Jing, Liu, Wei, Chen, Gang, Gong, Mei, Wu, Peng, Zhu, Tao, Wang, Shixuan, Zhou, Jianfeng, Wang, Hui, Ma, Ding, Li, Kezhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452869/
https://www.ncbi.nlm.nih.gov/pubmed/28588720
http://dx.doi.org/10.3892/ol.2017.6032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452869/
https://www.ncbi.nlm.nih.gov/pubmed/28588720
http://dx.doi.org/10.3892/ol.2017.6032

Ejemplares similares